Technical Analysis for RANI - Rani Therapeutics Holdings, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | -4.33% | |
| Stochastic Reached Oversold | Weakness | -4.33% |
| Alert | Time |
|---|---|
| Down 5% | about 15 hours ago |
| Fell Below Lower Bollinger Band | about 15 hours ago |
| Down 3% | about 17 hours ago |
| Down 2 % | about 17 hours ago |
| Lower Bollinger Band Support | about 17 hours ago |
Get a Trading Assistant
- Earnings date: 05/08/2024
Rani Therapeutics Holdings, Inc. Description
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-103, a glucagon-like peptide-1 mimetic to treat type 2 diabetes; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was founded in 2012 and is headquartered in San Jose, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Diabetes Endocrine System Osteoporosis Peptide Hormones Growth Hormone Psoriatic Arthritis Glands Growth Hormone Deficiency Neuroendocrine Tumors Acromegaly Glucagon Hypoparathyroidism Neuroendocrinology Parathyroid Hormone
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.75 |
| 52 Week Low | 1.82 |
| Average Volume | 169,763 |
| 200-Day Moving Average | 3.51 |
| 50-Day Moving Average | 4.98 |
| 20-Day Moving Average | 6.62 |
| 10-Day Moving Average | 6.62 |
| Average True Range | 0.71 |
| RSI (14) | 44.13 |
| ADX | 29.02 |
| +DI | 24.61 |
| -DI | 24.56 |
| Chandelier Exit (Long, 3 ATRs) | 6.63 |
| Chandelier Exit (Short, 3 ATRs) | 7.56 |
| Upper Bollinger Bands | 7.65 |
| Lower Bollinger Band | 5.59 |
| Percent B (%b) | -0.03 |
| BandWidth | 31.10 |
| MACD Line | 0.28 |
| MACD Signal Line | 0.54 |
| MACD Histogram | -0.2614 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.55 | ||||
| Resistance 3 (R3) | 6.63 | 6.38 | 6.38 | ||
| Resistance 2 (R2) | 6.38 | 6.12 | 6.33 | 6.32 | |
| Resistance 1 (R1) | 5.95 | 5.96 | 5.82 | 5.87 | 6.27 |
| Pivot Point | 5.70 | 5.70 | 5.63 | 5.65 | 5.70 |
| Support 1 (S1) | 5.27 | 5.44 | 5.15 | 5.19 | 4.79 |
| Support 2 (S2) | 5.02 | 5.28 | 4.98 | 4.74 | |
| Support 3 (S3) | 4.59 | 5.02 | 4.68 | ||
| Support 4 (S4) | 4.51 |
